For insurers, telecom operators, and pharmaceutical groups
DossiMed is a production-grade medication-adherence and prescription-management platform, built for European compliance from day one and natively localized for French, Arabic, and English markets. Available for white-label deployment, exclusive licensing, or full IP transfer.
Health insurers and mutual funds
Adherence drift among chronic patients drives a meaningful share of avoidable claim costs. DossiMed gives you a deployable engagement layer that escalates from push to WhatsApp to automated voice calls.
Telecom operators (MENA, Maghreb, francophone Africa)
Telecom operators with tens of millions of subscribers need a packaged health product that speaks Arabic natively, integrates with WhatsApp, and ships in weeks rather than years.
Pharmaceutical groups and patient-engagement programs
A five-point improvement in adherence translates directly into additional months of therapy and protected revenue on a chronic franchise. DossiMed plugs into existing patient-support programs without crossing the medical-device threshold.
A two-stage AI pipeline turns a phone photo of a paper prescription into a validated, structured medication list. Document Intelligence handles the visual layer; a frontier language model handles the semantic layer. No personally identifying data leaves the EU perimeter.
Push notification at the dose time. If unacknowledged, escalation to WhatsApp with a short conversational message. If still unacknowledged on critical doses, automated voice call in the patient's locale with multilingual synthesized voices.
A web portal where prescribing physicians can view the structured prescription, adherence telemetry, and patient-shared lab results. Read-only, audit-logged, RBAC-controlled.
GDPR Article 13, 9, and 27 compliant. Two-checkbox health-data consent with persistence. Automatic data-retention purge jobs. Article 20 portability through a one-click export. Data Processing Agreements signed with all subprocessors. Hosted on Supabase eu-central-2 (Zurich, Switzerland — GDPR adequacy decision).
Run DossiMed under your brand, in your locale, on the infrastructure of your choice.
Suited for: Telecom operators, regional insurers, sovereign health programs
Take exclusive rights to operate DossiMed in a defined territory or therapeutic area.
Suited for: Pharmaceutical groups for a chronic franchise, regional health-tech holdings
Acquire the full intellectual property of the platform — code, brand, infrastructure, and documentation — for unrestricted strategic use.
Suited for: Strategic acquirers building a long-term health vertical
French, Arabic, and English are first-class locales. The Arabic experience is built natively, not retrofitted. Right-to-left layout, locale-appropriate synthesized voices, and culturally adapted message templates ship out of the box.
Compliance was a design constraint, not an audit response. The platform ships with consent persistence, automatic retention purges, Article 20 export, an EU representative under Article 27, and signed DPAs with all subprocessors.
DossiMed reproduces the prescriber's instructions and helps the patient follow them. It does not diagnose, calculate doses, flag contraindication risks, or interpret lab values. This sub-MDR positioning means integration in weeks, not the multi-year clinical-evaluation cycle of a Class IIa device.
Document Intelligence, the frontier LLM, the messaging providers, and the database layer are all swappable. A buyer can re-host the platform in a sovereign cloud or with an internal LLM without rewriting the core application code.
Primary region: Supabase eu-central-2, Zurich, Switzerland. Switzerland holds a GDPR adequacy decision under Article 45, qualifying it as a permitted destination for European health data without supplementary measures.
DossiMed is published by REC, a Tunisian SUARL operating under the "totalement exportatrice" export regime. The platform is structurally oriented toward export markets, with all rights consolidated at the entity level for clean transferability.
Available under NDA to qualified counterparties: GDPR processing registry, Data Protection Impact Assessment, technical and organizational measures inventory, subprocessor list, draft Asset Purchase Agreement template, IP chain-of-title evidence pack.
Why a Supabase-first edge-functions architecture is uniquely suited for a portable, sovereign-cloud-ready health platform.
Read →Why push notifications alone do not move adherence numbers, and how a three-tier escalation pyramid changes the curve.
Read →A two-stage pipeline that turns a creased phone photo into structured medical data, while keeping personal data off the AI provider's servers.
Read →Share your details and preferred engagement model. We will reply with a tailored brief.
A six-page document covering technical architecture, compliance posture, and the three engagement models. Sent under a light NDA.